Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INM InMed Pharmaceuticals	$2.23 -0.9%	$2.75	$1.72 ▼ $15.70	$4.46M	0.29	1.51 million shs	56,009 shs
MTNB Matinas Biopharma	$1.47 -8.1%	$0.94	$0.47 ▼ $8.39	$7.50M	1.32	298,222 shs	345,996 shs
SKVI Skinvisible	$0.19	$0.21	$0.16 ▼ $0.85	$1.02M	2.05	265 shs	20 shs
VAXX Vaxxinity	$0.04 +42,900.0%	$0.01	$0.00 ▼ $0.15	$5.45M	-24.16	4,958 shs	101 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INM InMed Pharmaceuticals	+0.45%	-5.06%	-18.18%	-14.12%	-19.64%
MTNB Matinas Biopharma	+41.33%	+66.88%	+55.05%	+144.45%	+759.99%
SKVI Skinvisible	0.00%	-16.94%	-5.40%	-10.16%	-68.47%
VAXX Vaxxinity	-99.60%	0.00%	0.00%	-50.00%	-99.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INM InMed Pharmaceuticals	0.1026 of 5 stars	0.0	2.0	0.0	0.0	0.6	0.0	0.6
MTNB Matinas Biopharma	0.75 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.6
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INM InMed Pharmaceuticals	0.00	N/A	N/A	N/A
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
SKVI Skinvisible	0.00	N/A	N/A	N/A
VAXX Vaxxinity	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INM InMed Pharmaceuticals	$4.60M	0.97	N/A	N/A	$20.64 per share	0.11
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
SKVI Skinvisible	$20K	51.08	N/A	N/A	($1.86) per share	-0.10
VAXX Vaxxinity	N/A	N/A	N/A	N/A	$0.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INM InMed Pharmaceuticals	-$7.68M	-$12.09	N/A	∞	N/A	-168.87%	-107.93%	-82.97%	9/26/2025 (Estimated)
MTNB Matinas Biopharma	-$22.94M	-$3.86	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
SKVI Skinvisible	-$570K	-$0.10	N/A	∞	N/A	-2,780.00%	N/A	-359.02%	N/A
VAXX Vaxxinity	-$56.93M	-$0.45	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest SKVI, VAXX, INM, and MTNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	SKVI Skinvisible	N/A	-$0.05	N/A	-$0.05	N/A	$0.01 million
5/12/2025	Q3 2025	INM InMed Pharmaceuticals	N/A	-$1.94	N/A	-$1.94	N/A	$1.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INM InMed Pharmaceuticals	0.06	3.49	3.04
MTNB Matinas Biopharma	N/A	5.53	5.53
SKVI Skinvisible	N/A	0.01	0.01
VAXX Vaxxinity	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INM InMed Pharmaceuticals	20.12%
MTNB Matinas Biopharma	11.77%
SKVI Skinvisible	N/A
VAXX Vaxxinity	82.95%

Insider Ownership

Company	Insider Ownership
INM InMed Pharmaceuticals	1.43%
MTNB Matinas Biopharma	4.60%
SKVI Skinvisible	53.00%
VAXX Vaxxinity	64.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INM InMed Pharmaceuticals	10	2.00 million	1.97 million	Not Optionable
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
SKVI Skinvisible	2	5.40 million	2.54 million	Not Optionable
VAXX Vaxxinity	90	126.75 million	45.55 million	Not Optionable

SKVI, VAXX, INM, and MTNB Headlines

Recent News About These Companies

Brain health

October 24, 2024 | newsweek.comN

Treatment Trials in Alzheimer's Disease

September 30, 2024 | msn.com

Is Vaxxinity Inc (VAXX) Stock a Good Investment?

September 19, 2024 | aaii.comA

Congress makes $4.5 trading stocks in a day; Here's the biggest winners

July 4, 2024 | finbold.comF

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

June 20, 2024 | globenewswire.com

Why Is Vaxxinity (VAXX) Stock Up 39% Today?

May 3, 2024 | investorplace.com

Why Is Vaxxinity (VAXX) Stock Down 58% Today?

April 22, 2024 | investorplace.com

Vaxxinity Plans to Delist Shares From Nasdaq

April 19, 2024 | marketwatch.com

Vaxxinity Issues Shareholder Letter

April 19, 2024 | globenewswire.com

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

April 19, 2024 | globenewswire.com

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

March 28, 2024 | globenewswire.com

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

March 27, 2024 | investorplace.com

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

March 27, 2024 | globenewswire.com

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

March 7, 2024 | globenewswire.com

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

February 15, 2024 | finance.yahoo.com

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | finance.yahoo.com

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | globenewswire.com

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

February 13, 2024 | finance.yahoo.com

Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

January 30, 2024 | finance.yahoo.com

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

January 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SKVI, VAXX, INM, and MTNB Company Descriptions

InMed Pharmaceuticals NASDAQ:INM

$2.23 -0.02 (-0.89%)

As of 03:26 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Matinas Biopharma NYSE:MTNB

$1.47 -0.13 (-8.13%)

As of 03:29 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Skinvisible OTCMKTS:SKVI

$0.19 0.00 (0.00%)

As of 08/11/2025

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

Vaxxinity NASDAQ:VAXX

$0.04 +0.04 (+42,900.00%)

As of 10:25 AM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time